Studies on mouse models with HCC reported that METTL3, by enhancing the translation of the epidermal growth factor receptor (EGFR) in lenvatinib-resistant HCC, promotes cell proliferation and inhibits apoptosis [79]. Here, METTL3 is linked to hepatocellular carcinoma.